Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid symbols : Ino save search
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Published: 2021-11-09 (Crawled : 13:15) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 4.79%
H: 7.71%
C: 0.71%
covid fda vaccine phase 3 ino-4800
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 0.99%
H: 1.41%
C: -0.98%
covid collaboration announces collaboration
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-10-12 (Crawled : 13:00) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 2.06%
H: 0.58%
C: -0.29%
covid vaccine ino-4800
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Published: 2021-10-11 (Crawled : 12:00) - prnewswire.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: -1.21%
H: 5.95%
C: 3.82%
covid vaccine phase 3 authorized ino-4800
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-08-26 (Crawled : 12:15) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 4.86%
H: 8.36%
C: -1.69%
covid vaccine phase 3 trial authorized ino-4800
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO’s COVID-19 DNA Vaccine Candidate
Published: 2021-08-09 (Crawled : 12:00) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: -1.16%
H: 8.32%
C: 4.77%
covid clinical trials china vaccine trial ino-4800 primec
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
INOVIO’s Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies
Published: 2021-05-12 (Crawled : 12:00) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 1.39%
H: 0.3%
C: -4.26%
covid vaccine ino-4800 preclinical pre-clinical
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
Published: 2021-05-10 (Crawled : 12:00) - prnewswire.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 2.04%
H: 3.0%
C: -4.58%
covid phase 2 positive vaccine trial ino-4800
INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
Published: 2021-04-15 (Crawled : 12:00) - inovio.com
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 11.09%
H: 5.6%
C: -8.25%
covid vaccine ino-4800 response
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
Published: 2021-01-04 (Crawled : 16:00) - biospace.com/
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 2.26%
H: 8.51%
C: 7.51%
covid china vaccine partnership commercialization ino-4800
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: 0.3%
covid china vaccine trial phase 2 ino-4800
INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
Published: 2020-12-03 (Crawled : 15:00) - biospace.com/
INO 2 d | $10.335 -6.64% 270K
|
Health Technology
|
| O: 2.29%
H: 9.28%
C: 2.25%
covid vaccine ino-4800
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.